Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...
SAN DIEGO, Calif.--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today presented positive real-world data from ongoing use of ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin delivery algorithm, for use in individuals aged 18 and above with type 2 ...
Tandem Diabetes Care, an insulin delivery and diabetes technology company, announced it received FDA clearance for the Android version of its mobile app Tandem Mobi. The system, powered by Control-IQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results